Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novavax Inc (NVAX) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance

Novavax IncTrade
Vanguard International High Dividend Yield ETFTrade

Price performance (Past 24H)

Key statistics

Novavax Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Novavax Inc trades at $7.94 (market cap $1.31B), while Vanguard International High Dividend Yield ETF trades at $104.49. The key difference: Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

NVAXVYMI
Market Cap
$1.31B
Sector
HealthBroad Market / Factor
52-Week High
$11.19$105.05
52-Week Low
$6.22$82.92
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Vanguard International High Dividend Yield ETF

VYMI trades at $104.69, up 0.1% on the day, with strong technical momentum as it approaches resistance at $105. The ETF has gained attention for its international dividend strategy, offering a 3.4% yield and delivering 55% total returns since previous coverage. Recent institutional buying and positive media sentiment highlight growing investor interest in international high-yield exposure.

The outlook remains positive given Vanguard's projection of international developed-market stocks outperforming US markets over the next decade. Key opportunities include diversification benefits and strong dividend growth, while risks center on currency fluctuations and global economic volatility. The ETF's technical strength and fundamental appeal support a constructive view for income-focused investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX

About Vanguard International High Dividend Yield ETF

VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.

Read more on VYMI